GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Sanofi SA (NAS:SNY) » Definitions » Construction In Progress

Sanofi (Sanofi) Construction In Progress

: $0 Mil (As of Jun. 2023)
View and export this data going back to 2002. Start your Free Trial

Sanofi's quarterly construction in progress increased from Jun. 2022 ($0 Mil) to Dec. 2022 ($3,174 Mil) but then declined from Dec. 2022 ($3,174 Mil) to Jun. 2023 ($0 Mil).

Sanofi's annual construction in progress declined from Dec. 2021 ($3,499 Mil) to Dec. 2022 ($3,174 Mil) but then increased from Dec. 2022 ($3,174 Mil) to Dec. 2023 ($3,761 Mil).

Sanofi Construction In Progress Historical Data

The historical data trend for Sanofi's Construction In Progress can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Sanofi Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Construction In Progress
Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 2,656.67 3,767.64 3,499.44 3,173.73 3,761.18

Sanofi Semi-Annual Data
Jun14 Dec14 Jun15 Dec15 Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Construction In Progress Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 3,499.44 - 3,173.73 - 3,761.18

Sanofi Construction In Progress Calculation

It records the cost of construction work, which is not yet completed (typically, applied to capital budget items). A construction in progress item is not depreciated until the asset is placed in service. Normally, upon completion, a construction in progress item is reclassified, and the reclassified asset is capitalized and depreciated.

Sanofi (Sanofi) Business Description

Industry
GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Sanofi SA (NAS:SNY) » Definitions » Construction In Progress
Comparable Companies
XPAR:VIRP LLY JNJ MRK ABBV LSE:AZN XSWX:ROG XSWX:NOVN PFE AMGN BMY GILD LSE:GSK TSE:4519 TSE:4568 SHSE:600276 BIIB XTER:BAYN TSE:4578 SHSE:600436
Traded in Other Exchanges
SNYNF:USA SNY:Mexico SANF:Italy 0A2V:UK SANp:UK 0O59:UK SAN:France SNW:Germany SNW2:Germany SNW:Germany SNW:Germany SNW2:Germany SNW:Germany SANO:Austria
Address
46, avenue de la Grande Armée, Paris, FRA, 75017
Website
https://www.sanofi.com
Sanofi develops and markets drugs with a concentration in oncology, immunology, cardiovascular disease, diabetes, and vaccines. However, the company's decision in late 2019 to pull back from the cardio-metabolic area will likely reduce the firm's footprint in this large therapeutic area. The company offers a diverse array of drugs with its highest revenue generator, Dupixent, representing just over 15% of total sales, but profits are shared with Regeneron. About 40% of total revenue comes from the United States and 25% from Europe. Emerging markets represent the majority of the remainder of revenue.